| 1 Reduction in uterine volume |
|
|
Other data |
No numeric data |
| 2 Reduction in fibroid volume |
|
|
Other data |
No numeric data |
| 3 Haemoglobin (g/dL) |
2 |
173 |
Mean Difference (IV, Random, 95% CI) |
0.93 [0.52, 1.35] |
| 4 Reduction in menstrual bleeding (PBAC < 75) |
1 |
|
Odds Ratio (M‐H, Random, 95% CI) |
Subtotals only |
| 4.1 Ulipristal acetate 5 mg |
1 |
143 |
Odds Ratio (M‐H, Random, 95% CI) |
41.41 [15.26, 112.38] |
| 4.2 Ulipristal acetate 10 mg |
1 |
146 |
Odds Ratio (M‐H, Random, 95% CI) |
78.83 [24.02, 258.74] |
| 5 Change in menstrual blood loss from baseline to treatment end |
1 |
22 |
Mean Difference (IV, Random, 95% CI) |
‐166.9 [‐277.60, ‐56.20] |
| 6 Serious adverse events |
3 |
|
Odds Ratio (M‐H, Random, 95% CI) |
Subtotals only |
| 6.1 Breast cancer |
1 |
241 |
Odds Ratio (M‐H, Random, 95% CI) |
0.08 [0.00, 2.04] |
| 6.2 Uterine haemorrhage |
2 |
274 |
Odds Ratio (M‐H, Random, 95% CI) |
0.24 [0.00, 12.70] |
| 6.3 Ovarian haemorrhage |
1 |
241 |
Odds Ratio (M‐H, Random, 95% CI) |
0.76 [0.03, 18.84] |
| 6.4 Fibroid protruding through cervix |
1 |
241 |
Odds Ratio (M‐H, Random, 95% CI) |
0.08 [0.00, 2.04] |
| 6.5 Menometrorrhagia |
1 |
241 |
Odds Ratio (M‐H, Random, 95% CI) |
0.08 [0.00, 2.04] |
| 6.6 Hyperplasia |
2 |
263 |
Odds Ratio (M‐H, Random, 95% CI) |
0.38 [0.02, 8.38] |
| 7 Other adverse events |
3 |
|
Odds Ratio (M‐H, Random, 95% CI) |
Subtotals only |
| 7.1 Headache |
3 |
304 |
Odds Ratio (M‐H, Random, 95% CI) |
0.78 [0.14, 4.30] |
| 7.2 Breast pain or tenderness |
2 |
274 |
Odds Ratio (M‐H, Random, 95% CI) |
1.76 [0.26, 11.70] |
| 7.3 Abdominal pain |
3 |
304 |
Odds Ratio (M‐H, Random, 95% CI) |
1.71 [0.36, 8.12] |
| 7.4 Pyrexia |
1 |
241 |
Odds Ratio (M‐H, Random, 95% CI) |
0.61 [0.12, 3.25] |
| 7.5 Hypercholesterolaemia |
1 |
241 |
Odds Ratio (M‐H, Random, 95% CI) |
1.25 [0.14, 10.96] |
| 7.6 Hypothyroidism |
1 |
241 |
Odds Ratio (M‐H, Random, 95% CI) |
3.36 [0.19, 60.73] |
| 7.7 Constipation |
2 |
274 |
Odds Ratio (M‐H, Random, 95% CI) |
0.60 [0.13, 2.79] |
| 7.8 Hypertriglyceridaemia |
1 |
241 |
Odds Ratio (M‐H, Random, 95% CI) |
0.99 [0.11, 9.11] |
| 7.9 Influenza |
1 |
241 |
Odds Ratio (M‐H, Random, 95% CI) |
0.99 [0.11, 9.11] |
| 7.10 Dizziness |
1 |
241 |
Odds Ratio (M‐H, Random, 95% CI) |
2.30 [0.12, 43.52] |
| 7.11 Nasopharyngitis |
2 |
274 |
Odds Ratio (M‐H, Random, 95% CI) |
0.45 [0.09, 2.31] |
| 7.12 Dysmenorrhoea |
1 |
241 |
Odds Ratio (M‐H, Random, 95% CI) |
0.05 [0.00, 1.02] |
| 7.13 Bladder pressure |
1 |
30 |
Odds Ratio (M‐H, Random, 95% CI) |
0.33 [0.03, 3.64] |
| 7.14 Micturition problem |
2 |
63 |
Odds Ratio (M‐H, Random, 95% CI) |
1.91 [0.28, 13.23] |
| 7.15 Lower back pain |
2 |
63 |
Odds Ratio (M‐H, Random, 95% CI) |
1.33 [0.29, 6.15] |
| 7.16 Proctodynia |
1 |
30 |
Odds Ratio (M‐H, Random, 95% CI) |
3.67 [0.14, 97.49] |
| 7.17 Coital pain |
1 |
30 |
Odds Ratio (M‐H, Random, 95% CI) |
6.6 [0.29, 150.07] |
| 7.18 Hot flushes |
1 |
30 |
Odds Ratio (M‐H, Random, 95% CI) |
25.24 [1.27, 503.38] |
| 7.19 Nausea |
2 |
63 |
Odds Ratio (M‐H, Random, 95% CI) |
1.97 [0.46, 8.46] |
| 7.20 Vomiting |
1 |
30 |
Odds Ratio (M‐H, Random, 95% CI) |
0.0 [0.0, 0.0] |
| 7.21 Diarrhoea |
2 |
63 |
Odds Ratio (M‐H, Random, 95% CI) |
3.62 [0.39, 33.89] |
| 7.22 Change of mood |
1 |
30 |
Odds Ratio (M‐H, Random, 95% CI) |
15.00 [1.54, 146.54] |
| 7.23 Lowered libido |
1 |
30 |
Odds Ratio (M‐H, Random, 95% CI) |
6.0 [0.58, 61.84] |
| 7.24 Weakness |
1 |
30 |
Odds Ratio (M‐H, Random, 95% CI) |
2.8 [0.43, 18.38] |
| 7.25 Fatigue |
1 |
30 |
Odds Ratio (M‐H, Random, 95% CI) |
1.73 [0.31, 9.57] |
| 7.26 Dental pain |
1 |
33 |
Odds Ratio (M‐H, Random, 95% CI) |
1.35 [0.12, 14.82] |
| 7.27 Vaginal infections |
1 |
33 |
Odds Ratio (M‐H, Random, 95% CI) |
2.44 [0.11, 55.56] |
| 7.28 Vaginal discharge |
1 |
33 |
Odds Ratio (M‐H, Random, 95% CI) |
1.35 [0.12, 14.82] |
| 8 Quality of life (Uterine Fibroid Symptoms and QoL questionnaire) |
|
|
Other data |
No numeric data |
